Healthcare provider profile · identity verified

Thomas M Masterson, MD

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · CLINTON, MD · NPI 1649224643

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Thomas M Masterson, MD received $119.72 in general payments during 2025 across 3 reported records.

ACADIA Pharmaceuticals Inc accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.

ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nuplazid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$119.72

3 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ACADIA Pharmaceuticals Inc	Unresolved — no canonical attribution shown	$119.72	100.0%	3	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$119.72	3

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
NUPLAZID Normalized: nuplazid	Drug	ACADIA Pharmaceuticals Inc	$119.72	3	2025
Source payment records 2025-02-01 · ACADIA Pharmaceuticals Inc · $29.40 · Open Payments source 2025-03-11 · ACADIA Pharmaceuticals Inc · $72.00 · Open Payments source 2025-04-23 · ACADIA Pharmaceuticals Inc · $18.32 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
NUPLAZID nuplazid	2025	Nuplazid	2024	47 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference	2025	NUPLAZID open payments reported associated product	CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852	Nuplazid · 2024 Exact normalized brand match · 1 Part D row	47	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1072	174
Eliquis	Apixaban	772	86
Gabapentin	Gabapentin	629	89
Amlodipine Besylate	Amlodipine Besylate	585	104
Mirtazapine	Mirtazapine	440	84
Clopidogrel	Clopidogrel Bisulfate	321	45
Levothyroxine Sodium	Levothyroxine Sodium	316	45
Tamsulosin Hcl	Tamsulosin Hcl	309	39
Metoprolol Tartrate	Metoprolol Tartrate	303	47
Metformin Hcl	Metformin Hcl	296	39
Furosemide	Furosemide	294	59
Potassium Chloride	Potassium Chloride	285	40
Trazodone Hcl	Trazodone Hcl	280	39
Levetiracetam	Levetiracetam	271	37
Losartan Potassium	Losartan Potassium	243	47
Metoprolol Succinate	Metoprolol Succinate	237	43
Lisinopril	Lisinopril	222	33
Baclofen	Baclofen	196	29
Escitalopram Oxalate	Escitalopram Oxalate	186	24
Carvedilol	Carvedilol	180	44
Divalproex Sodium	Divalproex Sodium	176	24
Hydralazine Hcl	Hydralazine Hcl	168	34
Pantoprazole Sodium	Pantoprazole Sodium	168	44
Duloxetine Hcl	Duloxetine Hcl	165	25
Latanoprost	Latanoprost	157	33
Midodrine Hcl	Midodrine Hcl	147	29
Allopurinol	Allopurinol	134	18
Enulose	Lactulose	130	14
Finasteride	Finasteride	124	13
Omeprazole	Omeprazole	122	37
Sevelamer Carbonate	Sevelamer Carbonate	119	27
Methenamine Hippurate	Methenamine Hippurate	118	suppressed
Benztropine Mesylate	Benztropine Mesylate	110	12
Donepezil Hcl	Donepezil Hcl	110	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	109	69
Sertraline Hcl	Sertraline Hcl	107	24
Hydrochlorothiazide	Hydrochlorothiazide	100	18
Jardiance	Empagliflozin	92	16
Quetiapine Fumarate	Quetiapine Fumarate	90	14
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	86	13
Fluoxetine Hcl	Fluoxetine Hcl	82	suppressed
Memantine Hcl	Memantine Hcl	82	12
Oxybutynin Chloride Er	Oxybutynin Chloride	81	14
Risperidone	Risperidone	78	14
Buspirone Hcl	Buspirone Hcl	77	15
Tizanidine Hcl	Tizanidine Hcl	75	11
Simvastatin	Simvastatin	71	suppressed
Xarelto	Rivaroxaban	71	suppressed
Calcium Acetate	Calcium Acetate	70	suppressed
Ondansetron Hcl	Ondansetron Hcl	68	38
Humalog Kwikpen U-100	Insulin Lispro	61	15
Atenolol	Atenolol	58	suppressed
Olanzapine	Olanzapine	58	suppressed
Aripiprazole	Aripiprazole	57	suppressed
Tramadol Hcl	Tramadol Hcl	57	14
Januvia	Sitagliptin Phosphate	56	suppressed
Glipizide	Glipizide	55	suppressed
Vancomycin Hcl	Vancomycin Hcl	55	13
Lantus	Insulin Glargine,hum.Rec.Anlog	54	14
Oxcarbazepine	Oxcarbazepine	52	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	51	23
Spironolactone	Spironolactone	51	suppressed
Tradjenta	Linagliptin	51	suppressed
Labetalol Hcl	Labetalol Hcl	50	suppressed
Pregabalin	Pregabalin	49	suppressed
Clonidine Hcl	Clonidine Hcl	48	16
Nifedipine Er	Nifedipine	48	13
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	48	27
Albuterol Sulfate	Albuterol Sulfate	47	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	47	suppressed
Entresto	Sacubitril/Valsartan	47	suppressed
Lactulose	Lactulose	47	17
Nuplazid	Pimavanserin Tartrate	47	suppressed
Diclofenac Sodium	Diclofenac Sodium	46	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	46	suppressed
Levofloxacin	Levofloxacin	46	26
Timolol Maleate	Timolol Maleate	44	11
Clozapine	Clozapine	43	suppressed
Myrbetriq	Mirabegron	42	suppressed
Constulose	Lactulose	40	suppressed
Pravastatin Sodium	Pravastatin Sodium	40	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	39	11
Humalog	Insulin Lispro	39	16
Prednisone	Prednisone	39	15
Sodium Chloride	0.9 % Sodium Chloride	39	24
Ciprofloxacin Hcl	Ciprofloxacin Hcl	38	22
Lacosamide	Lacosamide	38	suppressed
Montelukast Sodium	Montelukast Sodium	37	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	36	19
Azithromycin	Azithromycin	36	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	36	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	34	suppressed
Trulicity	Dulaglutide	34	suppressed
Divalproex Sodium Er	Divalproex Sodium	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	23
Ezetimibe	Ezetimibe	33	suppressed
Acetylcysteine	Acetylcysteine	32	suppressed
Famotidine	Famotidine	32	14
Haloperidol Lactate	Haloperidol Lactate	32	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	32	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	32	suppressed
Tivicay	Dolutegravir Sodium	31	suppressed
Brilinta	Ticagrelor	30	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	30	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	30	12
Bumetanide	Bumetanide	29	suppressed
Topiramate	Topiramate	29	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	28	suppressed
Ventolin Hfa	Albuterol Sulfate	28	suppressed
Diltiazem Hcl	Diltiazem Hcl	27	suppressed
Xifaxan	Rifaximin	27	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	27	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	26	suppressed
Sps	Sodium Polystyrene Sulfon/Sorb	26	17
Cefepime Hcl	Cefepime Hcl	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	24	suppressed
Lidocaine	Lidocaine	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	23	suppressed
Clonidine	Clonidine	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	23	suppressed
Metformin Hcl Er	Metformin Hcl	23	suppressed
Metolazone	Metolazone	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Ceftriaxone	Ceftriaxone Sodium	22	13
Meropenem	Meropenem	22	suppressed
Restasis	Cyclosporine	22	suppressed
Amiodarone Hcl	Amiodarone Hcl	21	suppressed
Cyclosporine	Cyclosporine	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	21	suppressed
Oxycontin	Oxycodone Hcl	21	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	20	suppressed
Leflunomide	Leflunomide	20	suppressed
Anastrozole	Anastrozole	19	suppressed
Incruse Ellipta	Umeclidinium Bromide	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Ozempic	Semaglutide	19	suppressed
Prazosin Hcl	Prazosin Hcl	19	suppressed
Alendronate Sodium	Alendronate Sodium	18	suppressed
Fluconazole	Fluconazole	18	15
Oxybutynin Chloride	Oxybutynin Chloride	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	13
Paliperidone Er	Paliperidone	18	suppressed
Scopolamine	Scopolamine	18	suppressed
Spiriva Handihaler	Tiotropium Bromide	18	suppressed
Celecoxib	Celecoxib	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Cholestyramine	Cholestyramine (With Sugar)	17	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	17	suppressed
Haloperidol	Haloperidol	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Alvesco	Ciclesonide	16	suppressed
Atrovent Hfa	Ipratropium Bromide	16	suppressed
Carbamazepine	Carbamazepine	16	suppressed
Valproic Acid	Valproic Acid	16	suppressed
Cephalexin	Cephalexin	15	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	15	suppressed
Insulin Lispro	Insulin Lispro	15	suppressed
Nystatin	Nystatin	15	11
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Amantadine	Amantadine Hcl	14	suppressed
Diazepam	Diazepam	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Prednisolone Acetate	Prednisolone Acetate	14	suppressed
Santyl	Collagenase Clostridium Hist.	14	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Admelog	Insulin Lispro	13	suppressed
Avonex (4 Pack)	Interferon Beta-1a	13	suppressed
Bicalutamide	Bicalutamide	13	suppressed
Cholestyramine Light	Cholestyramine	13	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Levocarnitine	Levocarnitine	13	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	13	suppressed
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	13	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	13	suppressed
Ranolazine Er	Ranolazine	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Ursodiol	Ursodiol	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Cefdinir	Cefdinir	12	suppressed
Ertapenem	Ertapenem Sodium	12	suppressed
Glipizide Er	Glipizide	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Renvela	Sevelamer Carbonate	12	suppressed
Velphoro	Sucroferric Oxyhydroxide	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Zenpep	Lipase/Protease/Amylase	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$119.72 · 3 records	ACADIA Pharmaceuticals Inc	NUPLAZID	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Nuplazid play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error